`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`
`
`
`Civil Action No.:
`
`
`
`
`
`
`SENJU PHARMACEUTICAL CO., LTD.,
`BAUSCH & LOMB, INC. and BAUSCH &
`LOMB PHARMA HOLDINGS CORP.
`
`
`Plaintiffs,
`
`v.
`
`LUPIN, LTD. and LUPIN
`PHARMACEUTICALS, INC.,
`
`
`Defendants.
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`Plaintiffs Senju Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated and Bausch &
`
`Lomb Pharma Holdings Corp. (collectively “Plaintiffs”) by way of Complaint against
`
`Defendants Lupin, Ltd. and Lupin Pharmaceuticals, Inc. (collectively “Lupin”) allege as follows:
`
`THE PARTIES
`
`1.
`
`Plaintiff Senju Pharmaceutical Co., Ltd. (“Senju”) is a corporation organized and
`
`existing under the laws of Japan, with a principal place of business at 2-5-8, Hirano-machi,
`
`Chuo-ku, Osaka 541-0046, Japan.
`
`2.
`
`Plaintiff Bausch & Lomb Incorporated (“B+L”) is a corporation organized and
`
`existing under the laws of New York, with a place of business at 1400 North Goodman St.,
`
`Rochester, New York 14609. B+L is the registered holder of approved New Drug Application
`
`No. 203168, which covers Prolensa®.
`
`3.
`
`Plaintiff Bausch & Lomb Pharma Holdings Corp. (“B+L Pharma Holdings”) is a
`
`corporation organized and existing under the laws of Delaware, with a place of business at 700
`
`Page 1 of 6
`
`SENJU EXHIBIT 2008
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`Case 1:14-cv-04149-JBS-KMW Document 1 Filed 06/26/14 Page 2 of 6 PageID: 2
`
`Route 202/206, Bridgewater, New Jersey 08807. B+L Pharma Holdings is a wholly-owned
`
`subsidiary of B+L.
`
`4.
`
`Upon information and belief, defendant Lupin, Ltd. is a corporation organized and
`
`existing under the laws of India, having a corporate headquarters at C/4 Laxmi Towers, Bandra
`
`Kurla Complex, Bandra (E), Mumbai 400 051.
`
`5.
`
`Upon information and belief, defendant Lupin Pharmaceuticals, Inc. is a
`
`corporation organized and existing under the laws of Virginia, having a principal place of
`
`business at 111 S. Calvert Street, 21st Floor, Baltimore, MD 21202. Upon information and belief,
`
`Lupin Pharmaceuticals, Inc. is a wholly-owned subsidiary of Lupin, Ltd.
`
`NATURE OF THE ACTION
`
`6.
`
`This is an action for infringement of United States Patent No. 8,669,290 (“the
`
`’290 patent”), arising under the United States patent laws, Title 35, United States Code, § 100 et
`
`seq., including 35 U.S.C. §§ 271 and 281. This action relates to Lupin Ltd.’s filing of an
`
`Abbreviated New Drug Application (“ANDA”) under Section 505(j) of the Federal Food, Drug,
`
`and Cosmetic Act (“the Act”), 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration
`
`(“FDA”) approval to market generic Bromfenac Ophthalmic Solution 0.07% (“Lupin’s generic
`
`bromfenac ophthalmic solution”).
`
`JURISDICTION AND VENUE
`
`7.
`
`8.
`
`This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).
`
`Upon information and belief, this Court has jurisdiction over Lupin, Ltd. Upon
`
`information and belief, Lupin Ltd. is in the business of manufacturing, marketing, importing and
`
`selling pharmaceutical drug products, including generic drug products. Upon information and
`
`belief, Lupin Ltd. directly manufactures, markets and sells generic drug products throughout the
`
`United States and in this judicial district, and this judicial district is a likely destination for
`
`-2-
`
`
`Page 2 of 6
`
`
`
`Case 1:14-cv-04149-JBS-KMW Document 1 Filed 06/26/14 Page 3 of 6 PageID: 3
`
`Lupin’s generic bromfenac ophthalmic solution. Upon information and belief, Lupin Ltd.
`
`purposefully has conducted and continues to conduct business in this judicial district.
`
`9.
`
`Upon information and belief, this court has jurisdiction over Lupin
`
`Pharmaceuticals, Inc. Upon information and belief, Lupin Pharmaceuticals, Inc. directly, or
`
`indirectly, manufactures, markets and sells generic drug products, including generic drug
`
`products manufactured by Lupin Ltd., throughout the United States and in this judicial district.
`
`Upon information and belief, Lupin Pharmaceuticals, Inc. purposefully has conducted and
`
`continues to conduct business in this judicial district.
`
`10.
`
`Upon information and belief, venue is proper in this judicial district under 28
`
`U.S.C. §§ 1391(c) and (d), and § 1400(b).
`
`COUNT FOR PATENT INFRINGEMENT
`
`11.
`
`The U.S. Patent and Trademark Office (“PTO”) issued the ’290 patent on March
`
`11, 2014. The ’290 patent claims, inter alia, formulations of bromfenac for ophthalmic
`
`administration. Plaintiffs hold all substantial rights in the ’290 patent and have the right to sue
`
`for infringement thereof. Senju is the assignee of the ’290 patent. A copy of the ’290 patent is
`
`attached hereto as Exhibit A.
`
`12.
`
`B+L is the holder of New Drug Application (“NDA”) No. 203168 for Prolensa®,
`
`which the FDA approved on April 5, 2013. In conjunction with NDA No. 203168, the ’290
`
`patent is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations
`
`(“the Orange Book”).
`
`13.
`
`Bromfenac Ophthalmic Solution 0.07% is sold in the United States under the
`
`trademark Prolensa®.
`
`14.
`
`Upon information and belief, Lupin Ltd. filed with the FDA ANDA No. 206027,
`
`under Section 505(j) of the Act and 21 U.S.C. § 355(j).
`-3-
`
`
`Page 3 of 6
`
`
`
`Case 1:14-cv-04149-JBS-KMW Document 1 Filed 06/26/14 Page 4 of 6 PageID: 4
`
`15.
`
`Upon information and belief, Lupin Ltd.’s ANDA No. 206027 seeks FDA
`
`approval to sell in the United States Lupin’s generic bromfenac ophthalmic solution, intended to
`
`be a generic version of Prolensa®.
`
`16.
`
`Bausch & Lomb received a letter from Lupin Ltd. dated May 13, 2014, purporting
`
`to be a Notice of Certification for ANDA No. 206027 (“Lupin’s notice letter”) under Section
`
`505(j)(2)(B)(ii) of the Act, 21 U.S.C. § 355(j)(2)(B)(ii), and 21 § C.F.R. 314.95(c).
`
`17.
`
`Lupin’s notice letter alleges that Lupin Ltd. has submitted to the FDA ANDA No.
`
`206027 seeking FDA approval to sell generic bromfenac ophthalmic solution, intended to be a
`
`generic version of Prolensa®.
`
`18.
`
`Upon information and belief, ANDA No. 206027 seeks approval of Lupin’s
`
`generic bromfenac ophthalmic solution that is the same, or substantially the same, as Prolensa®.
`
`19.
`
`Under 35 U.S.C. § 271(e)(2), Lupin Ltd. has infringed at least one claim of the
`
`’290 patent by submitting, or causing to be submitted to the FDA, ANDA No. 206027 seeking
`
`approval for the commercial marketing of Lupin’s generic bromfenac ophthalmic solution before
`
`the expiration date of the ’290 patent.
`
`20.
`
`Upon information and belief, Lupin’s generic bromfenac ophthalmic solution
`
`will, if approved and marketed, infringe at least one claim of the ’290 patent.
`
`21.
`
`Upon information and belief, Lupin Ltd. will, through the manufacture, use
`
`import, offer for sale and/or sale of Lupin’s generic bromfenac ophthalmic solution, directly
`
`infringe, contributorily infringe and/or induce infringement of at least one claim of the ’290
`
`patent.
`
`-4-
`
`
`Page 4 of 6
`
`
`
`Case 1:14-cv-04149-JBS-KMW Document 1 Filed 06/26/14 Page 5 of 6 PageID: 5
`
`22.
`
`Upon information and belief, Lupin Ltd.’s actions relating to ANDA No. 206027
`
`complained of herein were done with the cooperation, the participation, the assistance of, and at
`
`least in part for the benefit of Lupin Pharmaceuticals, Inc.
`
`WHEREFORE, Plaintiffs respectfully request that the Court enter judgment in their
`
`favor and against Defendants on the patent infringement claim set forth above and respectfully
`
`request that this Court:
`
`1.
`
`enter judgment that, under 35 U.S.C. § 271(e)(2), Lupin has infringed at least one
`
`claim of the ’290 patent through Lupin Ltd.’s submission of ANDA No. 206027 to the FDA to
`
`obtain approval for the commercial manufacture, use, import, offer for sale and/or sale in the
`
`United States of Lupin’s generic bromfenac ophthalmic solution before the expiration of the ’290
`
`patent;
`
`2.
`
`order that the effective date of any approval by the FDA of Lupin’s generic
`
`bromfenac ophthalmic solution be a date that is not earlier than the expiration of the ’290 patent,
`
`or such later date as the Court may determine;
`
`3.
`
`enjoin Lupin from the commercial manufacture, use, import, offer for sale and/or
`
`sale of Lupin’s generic bromfenac ophthalmic solution until expiration of the ’290 patent, or
`
`such later date as the Court may determine;
`
`4.
`
`enjoin Lupin and all persons acting in concert with Lupin from seeking, obtaining
`
`or maintaining approval of Lupin Ltd.’s ANDA No. 206027 until expiration of the ’290 patent;
`
`5.
`
`declare this to be an exceptional case under 35 U.S.C. §§ 285 and 271(e)(4) and
`
`award Plaintiffs costs, expenses and disbursements in this action, including reasonable attorneys
`
`fees;
`
`-5-
`
`
`Page 5 of 6
`
`
`
`Case 1:14-cv-04149-JBS-KMW Document 1 Filed 06/26/14 Page 6 of 6 PageID: 6
`
`6.
`
`award Plaintiff such further and additional relief as this Court deems just and
`
`proper.
`
`Dated: June 26, 2014
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`s/ John F. Brenner
`John F. Brenner
`PEPPER HAMILTON, LLP
`Suite 400
`301 Carnegie Center
`Princeton, New Jersey, 08543-5276
`(609) 951-4193
`brennerj@pepperlaw.com
`
`Attorneys for Plaintiffs
`SENJU PHARMACEUTICAL CO., LTD.,
`BAUSCH & LOMB, INC. and BAUSCH & LOMB
`PHARMA HOLDINGS CORP.
`
`
`
`
`
`-6-
`
`
`
`
`
`
`
`
`
`Of Counsel:
`Bryan C. Diner
`Justin J. Hasford
`FINNEGAN, HENDERSON,
`FARABOW, GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Page 6 of 6